December 2015 Issue of The Ophthalmologist

You might want to do the right thing and get stuck in – but there’s a bigger picture to be seen before you do.

A new tissue culture model of the retinal pigment epithelium may allow researchers to better understand the impacts of new interventions on the adult human retina

Pfizer and Allergan are to combine to form the world’s biggest pharma company, an eyecare behemoth – with a lower tax bill

Big data EMR mining (and some basic research) identifies a 50-year old drug that appears to protect against AMD development

Placental growth factor inhibitors might show efficacy in treating dry AMD as well as wet. Might aflibercept be repurposed?

Glaukos submits iDose IND to the FDA, Allergan bimatoprost implant shows promise, and ALPHAEON makes three deals in as many weeks

A new matrix therapy agent may promote corneal healing after epi-off CXL, improving patient comfort and recovery times

A specialized imaging technique has revealed two previously unknown structures of the cornea

5-year ATOM2 trial data confirms that 0.01% atropine is more effective at slowing myopia progression than 0.1% and 0.5% doses

Here, we recognize a year’s worth of innovation. Apps, IOLs, imagers, lasers, devices and drugs – the latest and greatest are all here. But which one came out on top this year?

Mitch Jackson discusses why he finds it harder to be a surgeon today than when he started out 27 years ago.

George discusses his current research focus in the field of cataract refractive surgery.

Jim discusses what it was like to step up to CEO position of international corporation AMO.

We get Bill’s perspective on what were his highlights from this year’s ESCRS congress.

A rising star amongst the CEDARS/ASPEN set, Loh practices at the front line of refractive/cataract surgery at the South Florida Vision Associates in Fort Lauderdale

Florian recalls experiences of dealing with difficult patients and talks of the advances in imaging and biometry.

Daniel Black discusses his experience with the ZEISS Cataract Suite markerless in the latest episode of In Conversation With…

CXL is effective in slowing and halting keratoconus and corneal ectasias – but the thinnest corneas can’t receive it, so we propose a new way of bringing CXL to those that need it most

Implanting a toric IOL during cataract surgery is great way of dealing with a patient’s corneal astigmatism – but off-axis rotation of the IOL can erode those benefits.

What does analysis of the last five years of literature on endophthalmitis tell us about the priorities of the field, and the contributors to it?

The Light for Sight foundation provides ophthalmologists around the world with CXL training and ensures that no young patient must go without treatment

Sitting Down With... Christoph and Thomas Bosshard, Oertli Instrumente AG, Berneck, Switzerland.

Highlights from Laboratoires Théa’s Satellite Education Program, “Ocular Surface: What’s New?” held on October 8, 2015, at the 7th EVER Congress, Nice, France.

Highlights from Oertli Instrumente AG’s Satellite Symposium, “The Future Way of Phaco and MIGS Surgeries,” held September 2015, Barcelona, Spain.